Studies have demonstrated that both MET overexpression and amplification are related to poor prognosis in patients with NSCLC (22–25), and MET amplification appears to be an independent marker of poor outcome following surgically resection of NSCLC (26–28). The gene discussed is MET; the disease is non-small cell lung carcinoma.